<DOC>
	<DOCNO>NCT02987413</DOCNO>
	<brief_summary>Background : Amyotrophic lateral sclerosis ( ALS ) neurodegenerative disease selectively affect motor neuron brain spinal cord , lead bulbar , respiratory , limb weakness . There effective treatment , disease usually progress death within 2 4 year . The therapeutic plasticity mesenchymal stem cell ( MSCs ) may attractive therapy complex disease , turn MSCs strong candidate cellular therapy ALS . Designâ€”A phase 1 open-safety clinical trial . 4 patient select accord restrict inclusion exclusion criterion 2 escalated infusion MSCs , follow period one year Methods - Primary endpoint : safety mesenchymal autologous stem cell infusion escalate two intrathecal administration patient ALS define severe adverse event ( SAe ) . Secondary endpoint : clinical response , laboratorial magnetic resonance imaging patient submit cellular escalating dos apply study . Quality life , accord El Escorial criterion , ALSFR scale functional scale . Conclusion : This study primary step large randomize double-blind clinical trial ALS . It expect confirm safety escalate MSCs therapy ALS patient , initial data efficacy addition improve quality life .</brief_summary>
	<brief_title>Escalated Application Mesenchymal Stem Cells Amyotrophic Lateral Sclerosis Patients</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Women males 18yearold . Diagnosis ALS agreement criterion `` EL SCORE '' Less 24 month evolution disease ( begin symptom ) . Good understanding protocol aptitude grant inform consent Infertile woman ( postmenopause hysterectomized ) Brazilian citizen permanent resident . Any significant medical condition ( congestive heart failure , angina , respiratory failure , others ) Any autoimmune disease Any malignant disease Systemic infection Mental illness Depressive state</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
</DOC>